| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Bevepreptide (100 nM; reoxygenation after 30 minutes of hypoxia, with monitoring for 10 minutes) trihydrochloride significantly reduced mitochondrial H2O2 release and H2O2/O2 ratio in permeabilized rat myocardial fibers after hypoxia-reoxygenation stress treatment [1]. Bevepreptide (100 nM; 3 days) trihydrochloride improved the mitochondrial ultrastructural integrity of corticospinal motor neurons (CSMN) in pprp-hTDP-43A315T-UeGFP mice by reducing mitochondrial aggregates, increasing the number of cristae and restoring the percentage of intact cristae, and increasing mitochondrial membrane polarization [1]. Bevepreptide hydrochloride (10 nM-1 μM; 3 days) dose-dependently improved mitochondrial motility in CSMN of mice expressing pprp-hTDP-43A315T-UeGFP, increased the proportion of cells containing mitochondria in axons, promoted axonal growth, and improved neurite branching and dendritic morphology [1]. Beveprepeptide hydrochloride (100 nM) binds to cardiolipin in hTDP-43 neurons and restores mitochondrial structure [2].
|
|---|---|
| ln Vivo |
Bevemipretide hydrochloride (2 mg/kg; subcutaneous injection; administered twice, 30 minutes before ischemia and 5 minutes before reperfusion) provides 81% protection against elevated blood urea nitrogen (BUN) caused by ischemia-reperfusion in rats with acute kidney injury and 86% protection against elevated creatinine caused by ischemia-reperfusion [1]. Bevemipretide hydrochloride (1-5 mg/kg; subcutaneous injection; administered twice, 20 hours apart) can prevent mitochondrial dysfunction caused by stroke by maintaining the respiratory control ratio in the rat brain [1]. Bevemipretide (1-5 mg/kg, intraperitoneal injection daily for 60 days) trihydrochloride exerts neuroprotective effects in ALS mice with TDP-43 pathology by maintaining the number of cortical spinal motor neurons, reducing astrocyte and microglial proliferation, decreasing the level of ubiquitinated protein inclusion bodies, and improving mitochondrial ultrastructure [1].
|
| Animal Protocol |
Animal/Disease Models:hsd: Sprague Dawley® (male, 275-300 g, ischemia-reperfusion induction) [1]
Doses: 2 mg/kg Route of Administration: Subcutaneous injection; two administrations: 30 minutes before ischemia and 5 minutes before reperfusion Experimental Results: Plasma urea nitrogen level decreased to 19.2 mg/dL after ischemia. Creatinine level decreased to 0.4 mg/dL after ischemia. Animal/Disease Models:hsd: Sprague Dawley® (male, 275-300 g, ET-1 induced middle cerebral artery occlusion) [1] Doses: 1 mg/kg; 5 mg/kg Route of Administration: Subcutaneous injection; two administrations: 48 hours and 28 hours before decapitation Experimental Results: The mitochondrial respiratory control rate (RCR) values of rats treated with 1 mg/kg or 5 mg/kg were comparable to those of the sham-operated control group. Animal/Disease Models:prp-hTDP-43A315T-UeGFP (female, C57BL/6J background, transgenic TDP-43 A315T mutant) [1] Doses: 1 mg/kg/day; 5 mg/kg/day Route of Administration: Intraperitoneal injection; once daily; starting at day 60 after birth for 60 days Experimental Results: CSMN retention increased to 51.4 (1 mg/kg/day) and 49.9 (5 mg/kg/day). Activated astrocytes decreased to 20.1 (1 mg/kg/day) and 24 (5 mg/kg/day). Activated microglia decreased to 9.1 (1 mg/kg/day) and 13.3 (5 mg/kg/day). Ubiquitinated protein inclusion bodies decreased to 26.1% (1 mg/kg/day) and 27.5% (5 mg/kg/day). Visible cristae mitochondria increased to 82.2%, and mitochondrial clumps per CSMN decreased to 0.69 (5 mg/kg/day). |
| References |
| Molecular Formula |
C31H48CL3N9O4
|
|---|---|
| Molecular Weight |
717.13
|
| CAS # |
2589640-11-7
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CC(C=C(C=C1C)O)=C1C[C@H](NC([C@H](N)CCCNC(N)=N)=O)C(N[C@H](C2=NC(CC3=CC=CC=C3)=NO2)CCCCN)=O.Cl.Cl.Cl
|
| Synonyms |
SBT-272 trihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3944 mL | 6.9722 mL | 13.9445 mL | |
| 5 mM | 0.2789 mL | 1.3944 mL | 2.7889 mL | |
| 10 mM | 0.1394 mL | 0.6972 mL | 1.3944 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
